HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
UnknownNCT01466205

Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder

This study has public registry information. It focuses on personality disorders and currently lists study information in the United States.

Personality disorders, Cognitive Impairments, ...DrugFrom 18 Years to 60 Years
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 60 years.

Listed locations
New York, United StatesSee all locations and recruitment

Compensation and expense reimbursement have not been verified for this summary.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateJanuary 2011
Recruitment status
Unknown
Enrollment listed in the registry
20
Sponsor
Larry J. Siever
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 60 Years
Official registry ID
NCT01466205
Official title
Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT01466205. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Status unknown

New York

Checked Official study record (opens in a new tab)
Registry details
Registry conditions (original wording)

Cognitive Impairments; Schizotypal Personality Disorder

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Larry J. Siever.

Does this study involve medication?

Yes. The study involves medication, including DAR-0100A and Placebo.

Who can participate?

Listed age limits: 18 years to 60 years.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.